GI
HUMA icon

GAMMA Investing’s Humacyte HUMA Stock Holding History

GAMMA Investing’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$190 Sell
243
-3,459
-93% -$3.21K ﹤0.01% 4097
2026
Q1 		$2.25K Buy
3,702
+2,313
+167% +$2.4K ﹤0.01% 3639
2025
Q4 		$1.33K Buy
+1,389
New +$1.97K ﹤0.01% 3717
2025
Q1 		– Sell
-112
Closed -$566 – 3833
2024
Q4 		$566 Sell
112
-117
-51% -$579 ﹤0.01% 3554
2024
Q3 		$1.25K Buy
229
+71
+45% +$468 ﹤0.01% 3198
2024
Q2 		$758 Buy
158
+46
+41% +$239 ﹤0.01% 3120
2024
Q1 		$348 Hold
112
– – ﹤0.01% 3157
2023
Q4 		$372 Buy
+112
New +$287 ﹤0.01% 3019

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

GAMMA Investing's HUMA Position: Q2 2026 in Review

GAMMA Investing reduced its Humacyte (HUMA) stake by 93% in Q2 2026, selling an estimated $3.21K and leaving 243 shares worth $190. The position accounts for ﹤0.01% of the portfolio, ranked #4097.

GAMMA Investing first reported a position in HUMA in Q4 2023 and has held it in 8 quarters since. The position peaked at $2.25K in Q1 2026. 161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • GAMMA Investing held 243 shares of Humacyte worth $190 as of Q2 2026.
  • GAMMA Investing sold 3,459 Humacyte shares in Q2 2026, an estimated $3.21K.
  • Humacyte made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #4097 holding.
  • GAMMA Investing first reported a position in Humacyte in Q4 2023 and has held it in 8 quarters since.
  • GAMMA Investing's Humacyte position peaked at $2.25K in Q1 2026.
  • 161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.